Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CorMedix Provides Update On CE Marking Process For Neutrolin

CorMedix Inc. (CRMD: Quote) on Thursday announced the receipt of a request for additional information and data, including six month stability data on the third and final test batch from TUV-SUD and MEB-Netherlands on the CE Mark application for Neutrolin in the EU.

Upon delivery of the requested information, the company believes that Neutrolin will enter a third and final round of review to finalize the CE Mark.

CorMedix anticipates providing such additional information and data in late third quarter or early fourth quarter of 2012.

As a result, CorMedix now expects a final review and determination regarding its CE Mark application by the end of 2012.

CorMedix said it is currently in the final stages of completing its commercialization plan and is in talks with several potential partners regarding the launch of Neutrolin in Europe.

Based on the status of such talks CorMedix continues to target a commercial launch for fourth quarter of 2012 or first quarter of 2013.

Click here to receive FREE breaking news email alerts for CorMedix Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After showing a notable move to the upside in early trading on Tuesday, stocks showed a substantial downturn over the course of the session. Concerns about the impact of new sanctions against Russia weighed on the markets. A day after lawmakers announced an agreement on compromise legislation to reform the Veterans Affairs Department, the Senate voted unanimously Tuesday to confirm a new head of the scandal-plagued department. Looking to increase pressure on Congress, the White House released a report on Tuesday warning of the economic costs of delaying action to address climate change.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.